Table 1. . Recent selected trials of antiangiogenic therapy for glioblastoma.
| Study, year (trial) | n | Design | Regimens | PFS | OS | Ref. | ||
|---|---|---|---|---|---|---|---|---|
| Median (months) | 6 months (%) | Median (months) | 9 months (%) | |||||
| Friedman et al., 2009 (BRAIN) | 167 | Phase II randomized in rGBM | Bev alone | NA | 42.6 | 10 | NA | [41] |
| Bev + IRI | NA | 50.3 | 9.5 | NA | ||||
| Kreisl et al., 2009 (NCI) | 67 | Phase II prospective in rGBM | Bev alone | 4 | 29 | 7.8 | NA | [43] |
| Field et al., (CABARET) | 122 | Phase II randomized in rGBM | Bev alone | NA | 24 | 6.4 | NA | [62] |
| Bev + carboplatin | NA | 26 | 6 | NA | ||||
| Taal et al., 2013 (BELOB) | 148 | Phase II randomized in rGBM | Bev alone | 3 | 18 | NA | 38 | [44] |
| Lomustine alone | 2 | 11 | NA | 43 | ||||
| Bev + lomustine | 4 | 41 | NA | 59 | ||||
| Wick et al., 2013 (AvaGlio) | 921 | Phase III randomized in nGBM | RT/TMZ + TMZ/Plc | 6.2 | NA | 16.8 | NA | [63] |
| XRT/TMZ + TMZ/Bev | 10 | NA | 16.9 | NA | ||||
| Gilbert et al., 2013 (RTOG 0825) | 637 | Phase III randomized in nGBM | RT/TMZ + TMZ/Plc | 7.3 | NA | 16.1 | NA | [64] |
| XRT/TMZ + TMZ/Bev | 10.7 | NA | 15.7 | NA | ||||
| Batchelor et al., 2013 (REGAL) | 325 | Phase III randomized in rGBM | Cediranib alone | 3.1 | NA | 8 | NA | [65] |
| Lomustine alone | 4 | NA | 9.4 | NA | ||||
| Cediranib + lomustine | 2.5 | NA | 9.8 | NA | ||||
| Stupp et al., 2013 (CENTRIC) | 545 | Phase III randomized in rGBM with methylated MGMT | RT/TMX + TMZ/CIL | 13.5 | NA | 26.3 | NA | [60] |
| TMZ/RT + TMZ/Plc | 10 | NA | 26.3 | NA | ||||
Bev: Bevacizumab; CIL: Cilengitide; IRI: Irinotecan; MGMT: O6-methylguanine-DNA methyltransferase; NA: Not applicable; nGBM: Newly diagnosed glioblastoma; OS: Overall survival; PFS: Progression-free survival; Plc: Placebo; rGBM: Recurrent glioblastoma; RT: Radiation therapy; TMZ: Temozolamide.